Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF

Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference

HFpEF Is the Substrate for Stroke in Obesity and Diabetes

Rana Assaly on LinkedIn: #hfpef #diabetes #francois #ada2023

PDF) Elafibranor improves diet-induced nonalcoholic

François Briand på LinkedIn: #tlm22 #obesity #nash #heartfailure

Physiogenex and Cardiomedex to present their original preclinical

Physiogenex on LinkedIn: Physiogenex is at ILC-EASL 2022 in London

Immunometabolic mechanisms of heart failure with preserved

Cardiomedex cardiovascular expert

Diabetes & Obesity in HFpEF: New targets in heart failure

Elafibranor improves diet-induced nonalcoholic steatohepatitis

News - Physiogenex

Frontiers Current Understanding of Molecular Pathophysiology of